Practical Insights in Novel Immune Therapies in Multiple Myeloma Workshop
![](https://www.myelomasociety.org/wp-content/uploads/2022/08/pexels-elina-sazonova-1850619-745x419.jpg)
Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this workshop is for you!
This high-impact educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
Preliminary Agenda
Our sponsors:
![](https://www.myelomasociety.org/wp-content/uploads/2021/10/bmslogo-300x300-1-300x300.jpg)
![](https://www.myelomasociety.org/wp-content/uploads/2021/10/jsn_logo_prof_vert_color_rgb-300x170.jpg)
![](https://www.myelomasociety.org/wp-content/uploads/2022/03/Supported-by-a-grant-from-Pfizer-Inc-300x169.png)
The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient population. Given the plethora of different drug products in this space, including antibody-drug conjugates, T cell engagers and CAR T cells, this is a busy landscape and requires specific education around patient characteristics, treatment selection, and toxicity management to provide the best treatment options for our patients.